Protalix BioTherapeutics Reviewing Partnering and Other Alternatives
CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE-AMEX:PLX) (TASE:PLX), confirms, in response to inquiries received
this morning and a report appearing in the Israeli press, that the company has
engaged Citigroup to assist it in reviewing a broad array of product
partnering, technology sharing and other strategic alternatives. There is no
assurance that Protalix will undertake any such strategic alternative.
Protalix will not comment further on this initiative unless future events
would make doing so appropriate.
Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx^®.
To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe-harbor provisions of the Private Securities Litigation Reform Act of
1995.The terms "anticipate," "believe," "estimate," "expect" and "intend" and
other words or phrases of similar import are intended to identify
forward-looking statements.These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made.These
statements are based on our current beliefs and expectations as to such future
outcomes.Factors that might cause material differences include, among others,
risks relating to potential strategic alternatives.The statements in this
release are valid only as of the date hereof and we disclaim any obligation to
update this information.
CONTACT: Investor Contact
The Trout Group, LLC
Press spacebar to pause and continue. Press esc to stop.